Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: CEDAX

Summary for Tradename: CEDAX

Suppliers: see list3
patent expirations by year for

Pharmacology for Tradename: CEDAX

Clinical Trials for: CEDAX

Short-term Antibiotic Therapy for Pyelonephritis in Childhood
Status: Terminated Condition: Pyelonephritis

Patients Response to Early Switch To Oral:Osteomyelitis Study
Status: Not yet recruiting Condition: Osteomyelitis

Multicenter Study Comparing Morbidity and Quality of Life Associated in the Treatment by Surgical Resection and the Conservative Treatment, After Favorable Evolution of Purulent Peritonitis That Originates From Diverticulitis Treated by Mini-invasive Surgery
Status: Recruiting Condition: Peritonitis; Diverticulitis

Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Status: Active, not recruiting Condition: Multiple Myeloma

Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
Status: Terminated Condition: Alzheimer┬┤s Disease

Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease
Status: Active, not recruiting Condition: Parkinson Disease

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease
Status: Completed Condition: Alzheimer's Disease

Esophageal High Resolution Manometry and Dysphagia
Status: Completed Condition: Dysphagia

Reirradiation and Erbitux in the HNSCC
Status: Recruiting Condition: Head Neck Cancer Squamous Cell.

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Status: Completed Condition: Occult Primary

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pernix Therap
ceftibuten dihydrate
CAPSULE;ORAL050685Dec 20, 1995RXYes<disabled><disabled>
Pernix Therap
ceftibuten dihydrate
FOR SUSPENSION;ORAL050686Dec 20, 1995DISCNNo5,599,557<disabled>Y<disabled>
Pernix Therap
ceftibuten dihydrate
FOR SUSPENSION;ORAL050686Dec 20, 1995RXYes5,599,557<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology